DPP-6 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human DPP-6 (UniProt P42658), expressed in HEK293 cells. A catalytically inactive KCND2 channel auxiliary subunit used in potassium channel gating studies, autoantibody characterisation, and antibody validation workflows.
Expression system
HEK293
Cat. #
REC-DPP6

In stock

SKU
REC-DPP6
$498.00

Target Overview

DPP-6 (UniProt P42658; gene DPP6) is an 865-amino-acid type II transmembrane glycoprotein and member of the prolyl oligopeptidase family. Despite its structural homology to dipeptidyl aminopeptidases, DPP-6 is catalytically inactive and carries no measurable dipeptidyl aminopeptidase activity. Its principal biological role is as an auxiliary (beta) subunit of voltage-gated Kv4 potassium channels: it promotes cell-surface trafficking of KCND2 (Kv4.2) and substantially modifies channel gating kinetics, accelerating both inactivation and recovery from inactivation. This recombinant is produced by transient expression in HEK293 cells, a mammalian system that supports the post-translational glycosylation and folding required for the native conformation of this membrane-associated auxiliary subunit. The full-length human sequence (865 residues) is expressed with an affinity tag to facilitate purification and quantification. Researchers use this recombinant in several contexts. As a well-defined antigen, it serves as a positive control and loading standard in Western blot and ELISA workflows validating anti-DPP6 antibodies — including the matched Triple Point Biologics antibody (SKU: RP-DPP6). It is also used as a capture or competition antigen in autoantibody detection assays relevant to anti-DPPX autoimmune encephalitis research. In biophysical studies, purified DPP-6 provides a defined protein source for surface plasmon resonance, co-immunoprecipitation, and pull-down experiments examining DPP-6/KCND2 complex assembly. Its confirmed lack of enzymatic activity makes it straightforward to deploy in binding assays without confounding proteolytic artefacts.

Background

DPP-6 was originally classified by sequence homology within the dipeptidyl peptidase IV family, but functional studies established unambiguously that it lacks catalytic dipeptidyl aminopeptidase activity (Wada et al., 1992; Qi et al., 2003). The protein instead functions as a channel-modifying auxiliary subunit: it associates with the pore-forming Kv4.2 (KCND2) alpha subunit, drives its trafficking to the plasma membrane, and markedly reshapes the channel's inactivation kinetics. These gating effects place DPP-6 at the centre of research into transient outward potassium currents (I_to) in excitable tissues. In cardiac electrophysiology, DPP-6 has attracted substantial interest as a research target. Rossetti et al. (2026, Sci Transl Med) demonstrated that DPP-6 regulates the balance between the sodium current (I_Na) and the transient outward current (I_to), with implications for understanding arrhythmogenesis at a mechanistic level. This work illustrates how recombinant DPP-6 and validated antibody reagents are used to dissect channel complex stoichiometry and subcellular localisation in cardiomyocyte models. In the central nervous system, DPP-6 is widely expressed in neurons where Kv4-mediated I_to currents shape dendritic excitability and action potential backpropagation. Lin et al. (2026, Int J Mol Sci) characterised DPP6-knockout mouse models displaying age-dependent sleep dysregulation and depression-associated phenotypes, linking DPP-6 to neurodegeneration research programmes. These studies rely on well-validated recombinant antigens for confirming antibody specificity in knockout-versus-wildtype comparisons — precisely the role this recombinant serves. DPP-6 is also studied as the target antigen in anti-DPPX autoimmune encephalitis, a rare but clinically distinct antibody-mediated neurological syndrome. Shi et al. (2026, Immun Inflamm Dis) conducted a systematic review of anti-DPPX encephalitis presentations, underscoring the ongoing need for well-characterised recombinant antigen for use in cell-based assays, immunofluorescence competition experiments, and ELISA-format autoantibody detection. Researchers requiring a validated antibody to accompany this recombinant in Western blot or IHC experiments can pair it with the Triple Point Biologics anti-DPP6 antibody (SKU: RP-DPP6), which was raised and validated against the human DPP-6 protein and is predicted to cross-react with mouse and rat orthologues.

Applications

  • Positive control antigen in Western blot validation of anti-DPP6 antibodies (pairs with TPB SKU RP-DPP6)
  • Capture antigen in ELISA-format anti-DPPX autoantibody detection assays
  • Competition antigen in cell-based assays for anti-DPPX autoimmune encephalitis research
  • Pull-down and co-immunoprecipitation experiments characterising DPP-6/KCND2 (Kv4.2) complex assembly
  • Surface plasmon resonance (SPR) or biolayer interferometry binding studies with Kv4 channel subunits or interacting partners
  • Loading standard for quantitative Western blot in DPP6-knockout vs. wildtype tissue comparisons
  • Recombinant antigen for immunofluorescence competition controls in autoantibody characterisation workflows

References

  1. Rossetti A et al. Dipeptidyl aminopeptidase-like protein 6 regulates the I(Na)-I(to) balance influencing cardiac electrophysiology and arrhythmogenesis. Sci Transl Med. 2026. doi:10.1126/scitranslmed.adn3180. PMID: 42054494.
  2. Lin L et al. DPP6 Loss Causes Age-Dependent Sleep Dysregulation and Depression-like Phenotypes Linked to Neurodegeneration. Int J Mol Sci. 2026. doi:10.3390/ijms27073224. PMID: 41977406.
  3. Shi D et al. Severe Abdominal Pain as a Prominent Clinical Manifestation of Anti-DPPX Autoimmune Encephalitis: A Case Report and Systematic Review. Immun Inflamm Dis. 2026. doi:10.1002/iid3.70472. PMID: 42281295.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight does recombinant DPP-6 run at on SDS-PAGE or Western blot?

The full-length 865-residue DPP-6 polypeptide has a predicted molecular weight of ~97 kDa, but the protein runs noticeably higher on SDS-PAGE — typically 105–115 kDa — due to N-linked glycosylation acquired during expression in HEK293 cells. If you treat the sample with PNGase F prior to electrophoresis, the band collapses toward the ~97 kDa backbone. When using this recombinant as a positive control alongside our matched antibody RP-DPP6, expect a single prominent band in the 105–115 kDa region under reducing conditions.

Which isoforms or processing variants of DPP-6 does this recombinant represent?

This construct (REC-DPP6) encodes the canonical 865-residue human DPP-6 isoform corresponding to UniProt P42658-1. DPP-6 has at least four described splice variants (DPP6-S, DPP6-L, DPP6-K, DPP6-E) that differ at the N-terminal cytoplasmic region; this recombinant represents the long form (DPP6-L), which carries the full intracellular N-terminus. If your experimental model preferentially expresses a shorter isoform, confirm isoform identity of your endogenous target before using this as a WB size reference.

Does recombinant DPP-6 have dipeptidyl aminopeptidase enzymatic activity I can measure in vitro?

No. DPP-6 is catalytically inactive despite its structural homology to prolyl oligopeptidases. The active-site serine that defines the S9B protease family is absent or non-functional in DPP-6, and no measurable dipeptidyl aminopeptidase activity has been detected against standard fluorogenic substrates (e.g., Gly-Pro-AMC or Ala-Pro-AMC). Do not use REC-DPP6 in enzymatic cleavage assays expecting turnover. Its validated research applications are protein–protein interaction studies, Kv4.2 channel trafficking assays, and antibody validation — not peptidase activity profiling.

What assay format and buffer are recommended for DPP-6 Kv4.2 binding or co-immunoprecipitation experiments?

For pull-down or co-IP experiments probing the DPP-6/Kv4.2 (KCND2) interaction, REC-DPP6 performs well in near-physiological buffers: 25–50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% CHAPS or 0.5% n-dodecyl-β-maltoside (DDM) to maintain the transmembrane segment in a soluble, folded state. The standard storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible as a dilution base. Glycerol concentrations above 5% in the final binding reaction can reduce hydrophobic interaction efficiency; dilute accordingly before adding to detergent-solubilized membrane fractions.

What starting concentration of recombinant DPP-6 is recommended for surface plasmon resonance or bio-layer interferometry binding kinetics?

For SPR or BLI experiments characterizing DPP-6 interactions with Kv4 channel subunits or auxiliary partners, a titration series of 10–500 nM REC-DPP6 is a practical starting range. The protein is supplied at >90% purity by SDS-PAGE, which is generally sufficient for kinetic measurements, but we recommend a size-exclusion polishing step if aggregates affect baseline stability. Running buffer should be matched to the storage buffer minus glycerol (50 mM Tris-HCl pH 7.5, 150 mM NaCl) to minimize bulk refractive index shifts. Regeneration conditions should be optimized empirically; 0.5 M NaCl or mild detergent washes are a reasonable starting point.

Can I use REC-DPP6 as a positive control for Western blot with the RP-DPP6 rabbit polyclonal antibody?

Yes — this is one of the primary design purposes of REC-DPP6. The matched antibody RP-DPP6 (/anti-dpp-6-rabbit-polyclonal-antibody) was raised and validated against the same human DPP-6 sequence expressed in this recombinant, making it a reliable positive control pairing. Load 50–200 ng of REC-DPP6 per lane alongside your cell lysate lanes. Expect a clean band at 105–115 kDa. Running a titration (50, 100, 200 ng) in parallel with lysate lets you confirm antibody linearity and verify that your endogenous band co-migrates with the recombinant standard.

How much recombinant DPP-6 should I load for Western blot to validate a new DPP-6 antibody?

For antibody validation workflows — including confirming specificity of RP-DPP6 or a third-party anti-DPP6 antibody — load a two-point or three-point titration of REC-DPP6: typically 25 ng, 100 ng, and 300 ng per lane. This range brackets the sensitivity of most HRP-conjugated secondary antibody systems and confirms dose-dependent signal. Because REC-DPP6 is >90–95% pure by SDS-PAGE, a single band at ~105–115 kDa with no major cross-reactive species confirms antibody specificity without ambiguity from contaminating proteins present in whole-cell lysates.

How should I store and handle recombinant DPP-6 to maintain integrity across multiple experiments?

REC-DPP6 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at −20°C in single-use aliquots. Repeated freeze-thaw cycles cause aggregation of the transmembrane-containing glycoprotein and should be strictly avoided. Upon first thaw, keep the protein on ice and use within 8 hours. If you need to prepare working dilutions, use the storage buffer as diluent and avoid diluting below ~10 µg/mL in the absence of a carrier protein, as nonspecific adsorption to tube surfaces becomes significant at lower concentrations. Endotoxin is <0.1 EU/µg by LAL assay.

Validation imagery coming soon

Western blot validation figures for REC-DPP6 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →